Breast Surgeons Live

 Back to Activities List

Session Title:
Neoadjuvant vs Surgery-First in Early Triple Negative/HER-2+ Tumors
Date & Time:
January 11, 2023, 7:00 PM ET
CME Deadline:
January 11, 2024
Log in to access members-only content.
Target Audience:
At the end of this activity, participants will be able to:
  • Identify the information needed to bridge the knowledge gap in the management of this patient population.
  • Seek further study and research in this area.
While use of chemotherapy in the neoadjuvant setting has increased in TNBC and in HER2+ breast cancer, controversy remains over the optimal approach (neoadjuvant chemotherapy versus upfront surgery) for patients with small tumors (<2cm) that are triple negative or HER2 positive. This session will discuss the pros and cons of neoadjuvant chemotherapy versus upfront surgery in patients with small TNBC or HER2+ breast cancer.
Welcome and Introduction
Gretchen Ahrendt, MD, FACS
Debate: NAC for Early HER2+ or TNBC vs Upfront Surgery for Early HER2+ or TNBC
Laurie Kirstein, MD, FACS; Mediget Teshome, MD, MPH, FACS
Case Discussion
All Faculty
Moderator—Gretchen Ahrendt, MD, FACS
University of Colorado Anschutz Medical Center
Aurora, CO
Laurie Kirstein, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
Mediget Teshome, MD, MPH, FACS
University of Texas MD Anderson Cancer Center
Houston, TX
Use the link below to view disclosure information for all individuals and groups involved in the planning, implementation, and evaluation of this educational activity.
View Disclosure Information (pdf)